SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...

Sign up to receive High Country News’ email newsletters and get on-the-ground reporting and investigations delivered to your inbox each week.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...

The orchestra is renowned for its full-blooded performances, yet yesterday evening it felt that the stakes were higher than usual for the ensemble that first captured the imagination of British ...

Some of our services are temporarily unavailable due to maintenance. Subscription sign-ups and account access are currently offline. We apologize for any inconvenience and appreciate your patience ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Also of note is the 30 UPF rating this base layer sports, meaning it’ll lend some additional protection over the more gossamer tops on the list. The pants also boast this rating, and though it ...

Gossamer also reported encouraging preclinical data related to the combination of seralutinib and Winrevair. Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, ...

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an ...